NCT06050122 2025-10-14Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin SyndromeSol-Gel Technologies, Ltd.Phase 3 Active not recruiting140 enrolled